Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

mor masses is a major unmet need in a wide range of settings. It is our belief that, as a result, this technology has the potential to provide a broadly active new modality to substantially improve patient outcomes in a variety of hard-to-treat tumor types. "

Phase III Study Design

The Phase III study design agreed with the FDA follows directly from the design of the previous study. The Phase III study will also enroll previously untreated patients with locally advanced disease. The primary objective of the study will be to demonstrate a statistically significant increase in 2-year event free survival (i.e. relapse, progression, or death) for patients treated with chemoradiation together with OncoVEX (GM-CSF) as compared to patients treated with chemoradiation alone. The study will involve approximately 400 patients with approximately 200 in each arm.

Phase I/II Study Design and Results

In a Phase I/II study, OncoVEX (GM-CSF) was administered by direct injection, at three dose levels, into tumor containing lymph nodes in combination with standard first line chemo radiotherapy every three weeks for four cycles. All patients then went for surgery. Of the 17 patients enrolled, 16 had Stage IV N2 or N3 disease. OncoVEX (GM-CSF) was shown to be well tolerated with no significant side effects in addition to those associated with chemoradiation. With respect to efficacy, 93% of patients had a complete pathological response at surgery, with five patients achieving a complete response after only 2 or 3 virus doses. No patient to date has had a loco-regional recurrence in the neck at a median follow up of 30 months, and the disease specific survival rate is currently 82%.

Dr Robert Coffin, Founder and Chief Technology Officer, for BioVex, said:

"Loco-regional control is extremely important in head and neck cancer where loco regional progr
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...   ... Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte Kette ... (NYSE: PHG, AEX: PHIA) gab heute seine ... bekannt, der vom 4. bis 8. März in ... Nr. 102 and 110 wird das Unternehmen ...
(Date:3/3/2015)... 2015 NASA astronaut Scott Kelly , who ... spend a year living and working on the International Space ... to 7 a.m. EDT Monday, March 9. Kelly ... completes the final weeks of his training. The interviews will ... Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... "Gene Therapy Market, 2015 - 2025" report ... Market, 2015-2025" report provides an extensive study on the ... has been carried out in this field for over ... (four available in Asian markets; one approved in the ...
(Date:3/3/2015)... 2015 Adaptive Biotechnologies announced today that ... Board of Director as Chair of the Audit Committee. ... Chad oversees all finance, treasury and accounting functions. Since ... finance, treasury and accounting functions, and led the finance ... 2013, he was named Puget Sound Business Journal,s CFO ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2
... Acquisition Extends the Company,s Suite of Products and Increases ... LAUDERDALE, Fla. and PHILADELPHIA, June 23 OmniComm Systems, ... in integrated electronic data capture (EDC) solutions for clinical ... ("ERT"), a global provider of technology and services that ...
... Pursue All Pharmaceutical and Health-Oriented Nutraceutical Uses of Naturlose ... Incorporated (Nasdaq: SPEX ), an innovator in ... and regulatory consulting services to food, supplement, biotechnology and ... 1996 license agreement pursuant to which it granted Arla ...
... YM BioSciences Inc. (NYSE Amex: YMI , ... that identifies and advances a diverse portfolio of ... today reported that its licensee for nimotuzumab, Daiichi-Sankyo ... commenced enrollment of a Phase II trial evaluating ...
Cached Biology Technology:OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology 2OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology 3OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology 4Spherix Announces Termination of Arla License Agreement 2Spherix Announces Termination of Arla License Agreement 3Spherix Announces Termination of Arla License Agreement 4YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 2YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 3YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 4YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 5
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... the University of Pennsylvania School of Medicine discovered that ... the internal molecular clock in mammals. What's more, this ... shed light on circadian rhythm disorders, including bipolar disorder. ... of metabolism, are reported in this week's issue of ...
... human bocavirus was found in nearly 5 percent of ... children. Researchers from the Centers for Disease Control ... Conference on Emerging Infectious Diseases , "Our preliminary data ... in Thailand, especially among young children," says Alicia Fry, ...
... the genome sequence of the bacterial pathogen Haemophilus ... of many other large, complex, medically, and commercially ... , However, the techniques used to derive these ... be unaware of potential errors lurking within the ...
Cached Biology News:Clock molecule's sensitivity to lithium sheds light on bipolar disorder 2Bocavirus infection may be associated with pneumonia in Thailand, especially in children 2Study suggests that publicly available genome data may contain small but significant errors 2
... of the routine trace metal analytical lab ... and simple to use instrumentation. The 7500ce ... challenging sample matrices found in the environmental ... toughest analytical challenges found in the clinical, ...
Polio component type I...
Choriongonadotropin (human, hCG)...
Complement factor B (human)...
Biology Products: